Tempus AI To Acquire Personalis In $1.5B Deal, Expanding Minimal Residual Disease Capabilities And Precision Medicine Platform
Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growthExpands Tempus’ reach across the
Tempus AI is buying a company called Personalis for $1.5 billion to get better tools for watching cancer in patients' blood. Two companies joining together can sometimes do bigger things, so watch if Tempus grows faster or helps more patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.